EpiCypher, Inc. – Trademark Portfolio

Entity Type: 03

EpiCypher, Inc. holds 15 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 12 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 9 trademarks are registered. Notable registered marks include CUTANA, CAPTIFY, EPIDYNE, VERSANUC, and EPICYPHER. The owner is based in Durham, NC.

P.O. Box 14453

Durham, NC 27709

15 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

EpiCypher, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (12 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (5 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does EpiCypher, Inc. have?

EpiCypher, Inc. has 15 U.S. trademarks filed with the USPTO. Of these, 9 registered, 4 abandoned, 2 cancelled.

What trademark classes does EpiCypher, Inc. file in?

EpiCypher, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are EpiCypher, Inc.'s most well-known trademarks?

EpiCypher, Inc.'s registered trademark portfolio includes well-known marks such as CUTANA, CAPTIFY, EPIDYNE, VERSANUC, and EPICYPHER. These are among 9 currently registered trademarks in the portfolio.

What is EpiCypher, Inc.'s trademark registration success rate?

EpiCypher, Inc. has a 60% trademark registration rate, with 9 out of 15 resolved applications resulting in successful registration. Currently, 0 applications are pending review.